Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| imm03 | Other Identifier | immunitor |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Medical University, Ukraine | OTHER |
| Immunitor USA Inc. | INDUSTRY |
| University of Stellenbosch | OTHER |
| Lisichansk Regional Tuberculosis Dispensary |
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to carry out multi-country (Ukraine and Mongolia), placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug resistant (MDR-TB) and TB-HIV and identify efficacy and safety of whole-cell, heat-killed Mycobacterium vaccae formulated as a pill (V7) and consequently conduct confirmatory trials in intended registration countries, such as China, Russia and South Africa, etc.
Main end-point is negative sputum conversion rate after one month in patients on V7 vs placebo arm, both arms will receive conventional anti-tuberculosis chemotherapy consisting of 1st and/or 2nd line TB drugs according to baseline diagnosis
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| V7: Heat-inactivated M. vaccae pill | Experimental | Daily pill of V7 together with standard tuberculosis therapy |
|
| Placebo pill | Placebo Comparator | one pill of placebo pill once per day together with standard of care TB drugs |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| V7 | Biological | One pill of V7 once daily for 30 days together with standard of care TB drugs |
|
| Measure | Description | Time Frame |
|---|---|---|
| bacillary sputum smear clearance | blinded assessment of sputum clearance score | two years |
| Measure | Description | Time Frame |
|---|---|---|
| changes in body weight | comparison of body weight between treatment arm and placebo | 2 years |
| changes in body mass index (BMI) | comparison of body mass index (BMI) between treatment arm and placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Immune correlates | Identify changes in immune cells (lymphocytes) resulting from V7 administration | 2 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aldar Bourinbaiar, PhD, MD/PhD | Immunitor LLC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Misheel Lung surgery hospital, | Ulaanbaatar | Ulaanbaatar | 21000 | Mongolia | ||
| Lisichansk Regional TB Dispensary |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24088075 | Background | Butov DA, Efremenko YV, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy. 2013 Oct;5(10):1047-54. doi: 10.2217/imt.13.110. | |
| 23782489 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D018088 | Tuberculosis, Multidrug-Resistant |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| Placebo | Biological |
|
| 2 years |
| changes in inflammation markers | changes in erythrocyte sedimentation (ERS) rate and leukocyte counts | 2 years |
| changes in liver function test | changes in ALT, AST and total bilirubin levels | 2 years |
| Lisichansk |
| 60071 |
| Ukraine |
| Efremenko YV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother. 2013 Sep;9(9):1852-6. doi: 10.4161/hv.25280. Epub 2013 Jun 19. |
| 22397570 | Background | Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YV, Jirathitikal V, Mishchenko VV, Kutsyna GA. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther. 2012 Mar;10(3):381-9. doi: 10.1586/eri.12.1. |
| 30514514 | Result | Atmakuri K, Penn-Nicholson A, Tanner R, Dockrell HM. Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India. Tuberculosis (Edinb). 2018 Dec;113:55-64. doi: 10.1016/j.tube.2018.08.013. Epub 2018 Aug 24. |
| 31890902 | Derived | Bourinbaiar AS, Batbold U, Efremenko Y, Sanjagdorj M, Butov D, Damdinpurev N, Grinishina E, Mijiddorj O, Kovolev M, Baasanjav K, Butova T, Prihoda N, Batbold O, Yurchenko L, Tseveendorj A, Arzhanova O, Chunt E, Stepanenko H, Sokolenko N, Makeeva N, Tarakanovskaya M, Borisova V, Reid A, Kalashnikov V, Nyasulu P, Prabowo SA, Jirathitikal V, Bain AI, Stanford C, Stanford J. Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month. J Clin Tuberc Other Mycobact Dis. 2019 Dec 12;18:100141. doi: 10.1016/j.jctube.2019.100141. eCollection 2020 Feb. |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |